1
|
Evaluation of Spironolactone Solid Dispersions Prepared by Co-Spray Drying With Soluplus® and Polyvinylpyrrolidone and Influence of Tableting on Drug Release. J Pharm Sci 2018; 107:2385-2398. [DOI: 10.1016/j.xphs.2018.04.028] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 04/12/2018] [Accepted: 04/27/2018] [Indexed: 11/18/2022]
|
2
|
Hallouard F, Dollo G, Brandhonneur N, Grasset F, Corre PL. Preparation and characterization of spironolactone-loaded nano-emulsions for extemporaneous applications. Int J Pharm 2014; 478:193-201. [PMID: 25448582 DOI: 10.1016/j.ijpharm.2014.11.046] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 11/05/2014] [Accepted: 11/08/2014] [Indexed: 11/30/2022]
Abstract
In neonates as well as in adults having swallowing difficulty, oral medication is given through a nasogastric tube making liquid formulations preferable. In this study, we present the high potential of nanometric emulsions formulated by spontaneous surfactant diffusion, as extemporaneous formulations of hydrophobic drug. Spironolactone used as hydrophobic drug model, was incorporated in oil before formulation at a concentration of 13.5mg/g oil. Then, all formulations were evaluated from pharmacotechnical and clinical standpoints, for their use in hospital or community pharmacy. The strength of this new liquid formulation lies on the simplicity, efficiency and reproducibility of their low energy process as on clinical aspects: high dose uniformity, facility to be administered through in nasogastric tube without any retention and a stability of 2 months at least compatible for an extemporaneous use. Moreover, this emulsion presented spironolactone content of 3.75 mg/ml among the most concentrated formulations published.
Collapse
Affiliation(s)
- François Hallouard
- Université de Rennes I, Laboratoire de Pharmacie Galénique, Biopharmacie et Pharmacie Clinique, Rennes, France
| | - Gilles Dollo
- Université de Rennes I, Laboratoire de Pharmacie Galénique, Biopharmacie et Pharmacie Clinique, Rennes, France; Centre Hospitalo-Universitaire de Rennes, Pôle Pharmacie, Rennes, France.
| | - Nolwenn Brandhonneur
- Université de Rennes I, Laboratoire de Pharmacie Galénique, Biopharmacie et Pharmacie Clinique, Rennes, France
| | - Fabien Grasset
- Université de Rennes I, Institut des Sciences Chimiques de Rennes, UMR/CNRS 6226, Rennes, France; CNRS, UMI 3629CNRS/Saint-Gobain, Laboratory for Innovative Key Materials and Structures-Link, National Institute of Material Science (NIMS), GREEN/MANA Room 512, 1-1 Namiki, 305-0044 Tsukuba, Japan
| | - Pascal Le Corre
- Université de Rennes I, Laboratoire de Pharmacie Galénique, Biopharmacie et Pharmacie Clinique, Rennes, France; Centre Hospitalo-Universitaire de Rennes, Pôle Pharmacie, Rennes, France
| |
Collapse
|
3
|
Jiang Q, Li Y, Fu Q, Geng Y, Zhao J, Ma P, Zhang T. In-vitroandin-vivostudy of amorphous spironolactone prepared by adsorption method using supercritical CO2. Drug Dev Ind Pharm 2013; 41:201-6. [DOI: 10.3109/03639045.2013.858731] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
4
|
|
5
|
ElShaer A, Hanson P, Mohammed AR. A systematic and mechanistic evaluation of aspartic acid as filler for directly compressed tablets containing trimethoprim and trimethoprim aspartate. Eur J Pharm Biopharm 2012. [PMID: 23207325 DOI: 10.1016/j.ejpb.2012.11.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The generally accepted paradigm of 'inert' and 'mono functional' excipient in dosage form has been recently challenged with the development of individual excipients capable of exhibiting multiple functions (e.g. binder-disintegrants, surfactant which affect P-gp function). The proposed study has been designed within the realm of multifunctionality and is the first and novel investigation towards evaluation of aspartic acid as a filler and disintegration enhancing agent for the delivery of biopharmaceutical class IV model drug trimethoprim. The study investigated powder characteristics using angle of repose, laser diffractometry and scanning electron microscopy (SEM). The prepared tablets were characterised using Heckel analysis, disintegration time and tensile strength measurements. Although Heckel analysis revealed that both TMP and TMP aspartate salt have high elasticity, the salt form produced a stronger compact which was attributed to the formation of agglomerates. Aspartic acid was found to have high plasticity, but its incorporation into the formulations was found to have a negative impact on the compaction properties of TMP and its salt. Surface morphology investigations showed that mechanical interlocking plays a vital role in binding TMP crystals together during compaction, while the small particle size of TMP aspartate agglomerates was found to have significant impact on the tensile strength of the tablets. The study concluded that aspartic acid can be employed as filler and disintegrant and that compactability within tablets was independent of the surface charge of the excipients.
Collapse
Affiliation(s)
- Amr ElShaer
- Aston Pharmacy School, Aston University, Birmingham, UK
| | | | | |
Collapse
|
6
|
Hettiarachchi J, Ramsay LE. Spironolactone response related to plasma canrenone concentration [proceedings]. Br J Clin Pharmacol 2012. [DOI: 10.1111/j.1365-2125.1979.tb00971.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
7
|
Impact of Excipient Interactions on Drug Bioavailability from Solid Dosage Forms. Pharm Res 2012; 29:2639-59. [DOI: 10.1007/s11095-012-0767-8] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2012] [Accepted: 04/24/2012] [Indexed: 02/07/2023]
|
8
|
Dong Y, Ng WK, Shen S, Kim S, Tan RBH. Controlled antisolvent precipitation of spironolactone nanoparticles by impingement mixing. Int J Pharm 2011; 410:175-9. [PMID: 21397674 DOI: 10.1016/j.ijpharm.2011.03.005] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2010] [Revised: 02/21/2011] [Accepted: 03/07/2011] [Indexed: 11/18/2022]
Abstract
Continuous antisolvent precipitation of spironolactone nanoparticles were performed by impingement mixing in this work. In the range of Reynolds numbers (Re) 2108-6325 for the antisolvent water stream and 1771-5313 for the solvent stream, i.e. acetonic drug solution, 302-360 nm drug nanoparticles were achieved. Increasing drug concentration from 25 to 50 and 100 mg/ml led to a significant size increase from 279.0±2.6 to 302.7±4.9 and 446.0±17.3 nm, respectively. "Two-step crystallization" was first observed for spironolactone in the water/acetone system: the drug was precipitated initially as spherical cluster, which rearranged into ordered cuboidal nanocrystals finally. The nanoformulation showed faster dissolution rate in comparison with the raw drug. By combining the impingement mixing and an on-line spray drying, a fully continuous process may be developed for mass-production of dried drug nanoparticles.
Collapse
Affiliation(s)
- Yuancai Dong
- Institute of Chemical and Engineering Sciences, 1 Pesek Road, Jurong Island, Singapore 627833, Singapore.
| | | | | | | | | |
Collapse
|
9
|
Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm 2009; 375:84-8. [DOI: 10.1016/j.ijpharm.2009.03.013] [Citation(s) in RCA: 110] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2008] [Revised: 03/11/2009] [Accepted: 03/12/2009] [Indexed: 11/21/2022]
|
10
|
Abstract
This review summarizes the present knowledge of some commonly used diuretics. Bendroflumethiazide and bumetanide are completely absorbed from the gut while the uptake of hydrochlorothiazide, chlorthalidone and furosemide averages about 65%. The degree of uptake of amiloride and spironolactone is unknown but exceeds 50%. Plasma t 1/2 of bumetanide and furosemide are approximately 1 h. The clinically important phase of the plasma concentration of bendroflumethiazide has a t 1/2 of 3 h, although a slower phase with a t 1/2 of 9 h has been described. Hydrochlorothiazide and amiloride, often used in combination, both have a t 1/2 of about 10 h. Canrenone, an active metabolite of spironolactone, has a t 1/2 of 15-20 h. Chlorthalidone is eliminated very slowly with a t 1/2 of about two days. This is partly caused by an extensive binding to carbonic anhydrase in the erythrocytes. The protein binding of bendroflumethiazide, bumetanide, canrenone and furosemide is approximately 95%. The binding of chlorthalidone and hydrochlorothiazide is about 75 and 40% respectively. All mentioned diuretics except spironolactone are in part eliminated renally, mainly via tubular secretion. This is the major elimination route for amiloride and hydrochlorothiazide, while it constitutes one third to two thirds for bendroflumethiazide, bumetanide and furosemide. Spironolactone is exclusively eliminated as metabolites.
Collapse
|
11
|
Gray V, Kelly G, Xia M, Butler C, Thomas S, Mayock S. The science of USP 1 and 2 dissolution: present challenges and future relevance. Pharm Res 2009; 26:1289-302. [PMID: 19165579 DOI: 10.1007/s11095-008-9822-x] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2008] [Accepted: 12/24/2008] [Indexed: 12/01/2022]
Abstract
Since its inception, the dissolution test has come under increasing levels of scrutiny regarding its relevance, especially to the correlation of results to levels of drug in blood. The technique is discussed, limited to solid oral dosage forms, beginning with the scientific origins of the dissolution test, followed by a discussion of the roles of dissolution in product development, consistent batch manufacture (QC release), and stability testing. The ultimate role of dissolution testing, "to have the results correlated to in vivo results or in vivo in vitro correlation," is reviewed. The recent debate on mechanical calibration versus performance testing using USP calibrator tablets is presented, followed by a discussion of variability and hydrodynamics of USP Apparatus 1 and Apparatus 2. Finally, the future of dissolution testing is discussed in terms of new initiatives in the industry such as quality by design (QbD), process analytical technology (PAT), and design of experiments (DOE).
Collapse
Affiliation(s)
- Vivian Gray
- V. A. Gray Consulting, Inc., 9 Yorkridge Trail, Hockessin, DE 19707, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Concheiro A, Llabres M, Vila-Jato JL, Martinez R, Blanco J. Dissolution Rate and Bioavailability of Spironolactone Tablets: Effect of Various Technological Factors. Drug Dev Ind Pharm 2008. [DOI: 10.3109/03639048709020588] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
13
|
|
14
|
Salole EG, Al-Sarraj FA. Effect of Solvent-Deposition on Spironolactone Crystal Form. Drug Dev Ind Pharm 2008. [DOI: 10.3109/03639048509087770] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
15
|
Drug-excipient interactions and their affect on absorption. PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY 2000; 3:336-345. [PMID: 11050458 DOI: 10.1016/s1461-5347(00)00301-1] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Excipient(s) are traditionally thought of as inert but they can have a tremendous impact on the ultimate pharmacological availability of a drug substance when added to a formulation. The magnitude of this effect will depend on the characteristics of the drug and on the quantity and properties of the excipients. The aim of this article is to identify the various physicochemical and physiological processes that can be altered by drug-excipient interactions and to explore mechanisms by which they might occur. The regulatory implications of drug-excipient interactions will also be discussed.
Collapse
|
16
|
Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability. Int J Pharm 1997. [DOI: 10.1016/s0378-5173(96)04862-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Yusuff NT, York P, Chrystyn H, Bramley PN, Swallow RD, Tuladhar BR, Losowsky MS. Improved bioavailability from a spironolactone beta-cyclodextrin complex. Eur J Clin Pharmacol 1991; 40:507-11. [PMID: 1884726 DOI: 10.1007/bf00315231] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The relative bioavailabilty of spironolactone from a complex with beta-cyclodextrin has been evaluated. Capsules containing 100 mg micronised spironolactone powder were compared with 100 mg spironolactone beta-cyclodextrin complex in 8 healthy volunteers by a single dose, double blind, crossover pharmacokinetic study. Subjects were randomly allocated to each preparation and crossed over after 2 weeks. Relative bioavailability was assessed by the measurement of serum canrenone concentrations. The mean relative bioavailability of the spironolactone cyclodextrin complex, compared to the micronised spironolactone powder, was 233%. Statistical analysis (Wilcoxon signed rank test) revealed that this difference was significant with a mean area under the serum concentration time curve of 3.90 and 1.88 mg.h.l-1 for the complex and micronised spironolactone powder, respectively. Four of the volunteer also received a 100 mg spironolactone tablet (Aldactone) under identical conditions. Pharmacokinetic analysis revealed that the mean relative bioavailability of the spironolactone beta cyclodextrin complex and micronised powder when compared with spironolactone tablets (Aldactone) was 252% and 124%, respectively. There was no change in the canrenone elimination half lives of each subject.
Collapse
Affiliation(s)
- N T Yusuff
- Postgraduate School of Studies in Pharmaceutical Technology School of Pharmacy, University of Bradford
| | | | | | | | | | | | | |
Collapse
|
18
|
Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. REVIEWS ON DRUG METABOLISM AND DRUG INTERACTIONS 1987; 5:273-302. [PMID: 3333882 DOI: 10.1515/dmdi.1987.5.4.273] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Spironolactone, a competitive aldosterone antagonist, has been used for almost 30 years in those disorders associated with primary or secondary hyperaldosteronism. This review is confined to its metabolism and biopharmaceutics in man. Spironolactone undergoes extensive metabolism with no unchanged drug appearing in the urine. Its metabolites can be divided into two main categories: those in which the sulfur of the parent molecule is removed and those in which the sulfur is retained. The dethioacetylated metabolite canrenone, belonging to the former category, was long considered to be the major active metabolite of spironolactone. For this reason pharmacokinetic studies have focussed on its kinetic behaviour. However, pharmacodynamic studies indicated that canrenone could only partly explain spironolactone's action. Furthermore, with the advent of modern high-performance liquid chromatographic techniques to measure canrenone concentrations, it was shown that previously employed assay techniques were unspecific and consequently considerably overestimated true canrenone levels. Recently, it was demonstrated that after a single oral dose of spironolactone, 7 alpha-thiomethylspirolactone is the main metabolite and that unchanged spironolactone reaches maximum serum concentrations which are in the same order of magnitude as canrenone. Both spironolactone and 7 alpha-thiomethylspirolactone are known to possess anti-mineralocorticoid activity, and they may be mainly responsible for the activity of spironolactone. It also appears likely that endocrine side effects of spironolactone, such as gynaecomastia, are mediated by these sulfur-containing compounds. The oral absorption of spironolactone is improved by using micronized drug or inclusion complexes of spironolactone with cyclodextrins. Concomitant food intake has also been shown to enhance the bioavailability, by increasing the absorption and decreasing the first-pass effect of spironolactone.
Collapse
Affiliation(s)
- H W Overdiek
- Clinical Pharmacokinetics and Toxicology Laboratory, Hospital of Sittard, The Netherlands
| | | |
Collapse
|
19
|
Nijkerk AJ, Vermeer JM, Imanse M, De Vos D. The bioavailability of two new preparations of spironolactone tablets. PHARMACEUTISCH WEEKBLAD. SCIENTIFIC EDITION 1983; 5:210-2. [PMID: 6646986 DOI: 10.1007/bf02332945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Two new preparations of spironolactone tablets containing 25 and 100 mg of spironolactone have been characterized by their disintegration time, tablet spironolactone content, dissolution profile and bioavailability in comparison with two known spironolactone preparations as reference material. The preparations were found to possess almost identical characteristics, assuring a proper clinical use of the new tablet preparations. For spironolactone, a positive outcome of the in vitro dissolution test coincides with an excellent bioavailability.
Collapse
|
20
|
McInnes GT, Asbury MJ, Ramsay LE, Shelton JR, Harrison IR. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone. J Clin Pharmacol 1982; 22:410-7. [PMID: 7130430 DOI: 10.1002/j.1552-4604.1982.tb02694.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The bioavailability and pharmacologic activity of tablets containing micronized spironolactone chemical (median particle size 2.21 micrometers) were compared to those of tablets made from standard spironolactone chemical (median particle size 78.8 micrometers) in healthy men. Apart from particle size, all features of these tablets were identical. After 200-mg single doses, the bioavailability of micronized tablets was significantly higher than that of standard tablets. Furthermore, as assessed by 24-hour urine log10 10 Na/K ratio, the pharmacologic activity of micronized spironolactone was significantly greater than that of the standard formulation. The significant influence on renal antimineralocorticoid activity of raised plasma and urinary levels of canrenone, quantitatively the major active metabolite of spironolactone in man, emphasizes the clinical importance of the bioavailability of spironolactone preparations. Since this study, the process used in the manufacture of spironolactone (Aldactone) tablets has been under review.
Collapse
|
21
|
Ramsay LE, Hettiarachchi J. Spironolactone in thiazide-induced hypokalaemia: variable response between patients. Br J Clin Pharmacol 1981; 11:153-8. [PMID: 7213519 PMCID: PMC1401572 DOI: 10.1111/j.1365-2125.1981.tb01119.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
1 The influence of spironolactone 25, 50, 100 and 200 mg daily, and placebo, on plasma potassium and other variables was examined in a random crossover study of 15 hypertensive patients taking bendrofluazide 10 mg daily. 2 Spironolactone produced significant dose-related increases in plasma potassium and aldosterone, and reductions in plasma sodium and bicarbonate. 3 In 14 compliant patients plasma concentrations of the major metabolite canrenone were related linearly to the dose of spironolactone, and there was less than twofold variation between patients. The plasma canrenone concentration correlated negatively with body weight (r = -0.77, P less than 0.001). 4 The plasma potassium response to spironolactone varied sevenfold between compliant patients. The response correlated negatively with placebo plasma potassium (r = -0.62, P less than 0.02), positively with plasma canrenone (r = +0.55, P less than 0.05), but was unrelated to plasma aldosterone (r = -0.22). In one patient relative resistance to spironolactone was attributed to exaggerated secondary hyperaldosteronism induced by the drug. 5 The variability in response to spironolactone between patients is such that fixed dose thiazide-spironolactone combination tablets are unlikely to prevent hypokalaemia reliably.
Collapse
|
22
|
|
23
|
|